Vanguard Group Inc. Raises Holdings in Stoke Therapeutics, Inc. $STOK

Vanguard Group Inc. lifted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 7.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,163,874 shares of the company’s stock after acquiring an additional 217,616 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of Stoke Therapeutics worth $74,351,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in STOK. Marshall Wace LLP raised its stake in Stoke Therapeutics by 7.9% in the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after acquiring an additional 168,771 shares during the period. Goldman Sachs Group Inc. boosted its position in Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the period. Geode Capital Management LLC boosted its position in Stoke Therapeutics by 7.9% during the second quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock worth $11,044,000 after purchasing an additional 70,935 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Stoke Therapeutics by 67.3% in the third quarter. Assenagon Asset Management S.A. now owns 900,272 shares of the company’s stock worth $21,156,000 after purchasing an additional 362,299 shares in the last quarter. Finally, MPM Bioimpact LLC raised its position in shares of Stoke Therapeutics by 13.8% in the second quarter. MPM Bioimpact LLC now owns 789,698 shares of the company’s stock valued at $8,963,000 after purchasing an additional 95,710 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research note on Monday, January 5th. Chardan Capital lifted their price objective on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Guggenheim began coverage on shares of Stoke Therapeutics in a report on Thursday, February 5th. They set a “buy” rating and a $60.00 target price on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Finally, Canaccord Genuity Group lifted their price target on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.25.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 13,430 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.27, for a total value of $433,386.10. Following the completion of the transaction, the director directly owned 49,124 shares of the company’s stock, valued at $1,585,231.48. This trade represents a 21.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jonathan Allan sold 3,978 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.28, for a total transaction of $128,409.84. Following the transaction, the general counsel owned 11,831 shares of the company’s stock, valued at $381,904.68. This trade represents a 25.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 9.50% of the company’s stock.

Stoke Therapeutics Trading Up 2.4%

STOK stock opened at $35.48 on Friday. The firm has a 50 day moving average of $32.19 and a 200-day moving average of $28.94. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $39.81. The firm has a market capitalization of $2.03 billion, a P/E ratio of 52.96 and a beta of 1.07.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.